
|Articles|December 13, 2013
The Utility of the BRCAvantage Test
Author(s)Sukumar Nagendran, MD
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
Advertisement
Clinical Pearls
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
- BRCAvantage was launched in mid-October
- The test is a comprehensive solution to help patients and healthcare providers make clinical decisions regarding the prognostic nature of their disease course and treatment interventions
- BRCAvantage includes a complete analysis of BRCA1 and BRCA2 as well as targeted tests for other specific gene mutations and family gene mutations
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 Breast Cancer Trials Affirm De-Escalation, Earlier Switching
2
EHA 2026 Multiple Myeloma Highlights Have Worldwide Impact
3
Tec/Dara Offers a Path Forward in Relapsed Myeloma When CAR T Is Not an Option
4
FDA Grants Fast Track Designation to Givastomig for Frontline HER2-Negative Metastatic Gastric Cancer
5






































